I. Sturm

C. Köhne, H. Petrowsky, I. Sturm, 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice.

B. Dörken, R. Brown, I. Sturm, 1999, Blood.

Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.

B. Dörken, S. Hauptmann, C. Köhne, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombocytopenia as first manifestation of splenic angiosarcoma

S. Raffel, B. Hildebrandt, I. Sturm, 2009, Annals of Hematology.

Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.

B. Dörken, S. Hauptmann, P. Wust, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma

B. Dörken, S. Loening, C. Stephan, 2006, Cell Death and Differentiation.

The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines

B. Dörken, C. Köhne, I. Sturm, 2002, Oncogene.

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo

B. Dörken, K. Seeger, P. Daniel, 2000, Leukemia.

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

V. Diehl, T. Zenz, J. Zijlstra, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic E xpression P rofile o f p21 WAF1/CIP1 and Ki-67 Predicts Survival i n R ectal C arcinoma T reated W ith P reoperative Radiochemotherap y

S. Hauptmann, P. Wust, P. Schlag, 2003 .

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report

I. Sturm, J. Westermann, A. Pezzutto, 2008, Journal of medical case reports.

Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.

D. Cunningham, A. Cleton, I. Sturm, 2021, Cancer biotherapy & radiopharmaceuticals.

Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma

M. Storr, I. Sturm, R. Schindler, 2008, NDT plus.

Effect of dance on cancer-related fatigue and quality of life

I. Sturm, P. Thuss-Patience, B. Storek, 2014, Supportive Care in Cancer.

Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)

R. Issels, J. Hartmann, I. Sturm, 2015, Investigational New Drugs.

Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis

B. Dörken, M. Zeitz, H. Buhr, 2006, International Journal of Colorectal Disease.

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors

H. Lenz, A. Lockhart, A. Cleton, 2019, International journal of cancer.

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

S. Gettinger, N. Rizvi, M. Hellmann, 2015, Clinical lung cancer.

Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy

B. Dörken, S. Hauptmann, P. Wust, 2006, BMC Cancer.

Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene

B. Dörken, G. Wolff, I. Sturm, 2000, International journal of cancer.

Analysis of the p53/BAX pathway: Low BAX expression is a negative prognostic factor in patients with resected liver metastases of colorectal adenocarcinoma

B. Dörken, C. Köhne, G. Wolff, 1999 .

P-261Pharmacokinetics of regorafenib in the phase 3 CONCUR and CORRECT trials in patients with metastatic colorectal cancer (mCRC)

A. Cleton, I. Sturm, J. Lettieri, 2015 .